Tin tức & Cập nhật
Xem bài viết Tiêu hóa
Xem
Chỉ hiển thị Multimedia

Seladelpar benefit in PBC sustained at 3 years
22 May 2025
bởiAudrey Abella
The selective PPARδ* agonist seladelpar continues to demonstrate benefit in patients with primary biliary cholangitis (PBC) in the long-term pooled analysis from the ongoing open-label phase III ASSURE trial.








